Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
[Latest] Global Acute Respiratory Infection Market Size/Share Worth USD 20,796.6 Billion by 2033 at a 1.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
29 oct. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25 avr. 2024 10h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
22 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
19 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
18 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
11 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
05 mars 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
30 nov. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Cannula Market to hit USD 335 million by 2032, says Global Market Insights Inc.
15 août 2023 17h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Cannula Market size is estimated to record USD 335 million by 2032. The surging government support for providing primary healthcare services...